| HOME >> BIOLOGY >> TECHNOLOGY |
Research Shows New Class of Stent Effective in Preventing Thrombosis,
Restenosis, and Reocclusion
PARIS, Oct. 1 /PRNewswire/ -- CeloNova BioSciences, Inc., today announced that Masahiko Ochiai MD, Associate Professor, Division of Cardiology, Yokohama Hospital, Kanagawa, Japan has selected the CATANIA(TM) Coronary Stent System featuring NanoThin Polyzene(R)-F for treating a patient with a chronic total occlusion (CTO) during a live case symposium at the Paris Cardiovascular Interventions (Francophone) Congress. The CATANIA(TM) Coronary Stent System carries a CE Mark and is currently available for sale in Europe.
(Photo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080-a )
(Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b )
Chronic total occlusion is defined as any artery where blood flow has been completely blocked for greater than 30 days. These types of lesions are exceptionally difficult to treat with percutaneous intervention (angioplasty) because of the challenges physicians face in crossing the lesion to move the catheter into place for proper stent deployment. The CATANIA(TM) Stent was selected for this live case because Polyzene(R)-F makes it highly lubricious and delivers low restenosis rates, excellent anti-thrombosis rates, and other clinical benefits that approach or, in some cases, may exceed those of DES, while addressing some of the significant ongoing concerns with current DES technology such as product cost, risk for thrombosis, and serious challenges associated with costly long-term dual anti-platelet therapy following treatment.
"The CATANIA(TM) Stent has superb pushability, trackability, and
flexibility. You can feel that the Polyzene(R)-F surface is slicker than
other stents," said Thierry Corcos,
'/>"/>
| SOURCE CeloNova BioSciences, Inc. Copyright©2008 PR Newswire. All rights reserved |